Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenvatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 0.94 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 0.94 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 0.94 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.94 |
| ▸ | RET | P07949 | 6/20 | 0.94 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.94 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.94 |
| ▸ | KIT | P10721 | 3/20 | 0.94 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.94 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.94 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.94 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.94 |
| ▸ | STK10 | O94804 | 2/20 | 0.94 |
| ▸ | ABL1 | P00519 | 2/20 | 0.94 |
| ▸ | BCR | P11274 | 2/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.94 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.94 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.94 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenvatinib SCHEMBL865174 | 1.00 | FGFR4 (0.94) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29368684 | 1.00 | FGFR4 (0.94) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL3928020 | 0.97 | FGFR4 (0.91) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL864638 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29349806 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL29372021 | 0.97 | FGFR4 (1.00) | FGFR4RETKDRFGFR1PDGFRB | |
| Lenvatinib SCHEMBL1389214 | 0.96 | FGFR4 (0.98) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL28586143 | 0.92 | FGFR4 (0.91) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL1248140 | 0.90 | FGFR4 (0.87) | FGFR4RETKDRFGFR1PDGFRB | |
| SCHEMBL30083661 | 0.89 | FGFR4 (0.86) | FGFR4RETKDRFGFR1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2812 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-4168008-B1 | A COMBINATION OF BELZUTIFAN AND LENVATINIB FOR USE IN TREATING CANCER | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-12569575-B2 | Radiopaque particle compositions and uses thereof | GUSTAVE ROUSSY TRANSFERT (FR) | 2026-03-10 | — | — | US | claimed |
| CN-112142662-B | Preparation method of lervatinib mesylate | 南京法恩化学有限公司 | 2022-03-08 | — | — | CN | claimed |
| US-11266743-B2 | Peptide compositions and methods of use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-03-08 | — | — | US | claimed |
| CN-114144176-A | Compounds for inhibiting FGFR4 | 拓臻制药公司 | 2022-03-04 | — | — | CN | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957329-A1 | COMPOSITION FOR TREATING CANCER, APPLICATION THEREOF, AND DRUG | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| WO-2022020720-A9 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-02-17 | — | — | WO | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| US-20220040168-A1 | TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-02-10 | — | — | US | claimed |
| WO-2022022367-A1 | METHOD FOR PREPARING HIGH-PURITY CRYSTAL | 药源药物化学（上海）有限公司 | 2022-02-03 | — | — | WO | claimed |
| WO-2022020720-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-01-27 | — | — | WO | claimed |